KURZMELDUNGEN - Wirtschaft: Roche baut Produktion in den USA weiter aus
Die neuesten Meldungen.
Roche, the parent company of Genentech, announced on Thursday (20th August) that it is investing approximately $750 million in a new facility for packaging and finalizing medicinal products at its campus in Hillsboro, Oregon. This investment aims to add through-through "filling capacity" and expand the company's ability to support the future pipeline of innovative medicines from Roche and Genentech.
Roche disclosed these details about its expansion plans in the United States, following its earlier announcement in April 2025 that it would invest $50 billion there. The company is constructing a new production facility in Holly Springs, North Carolina, set to open in 2029 with 500 employees. This new plant will primarily focus on manufacturing syringes for the treatment of obesity.
Currently, Roche and Genentech have 13 production sites and 15 research and development sites in the United States. The company employs around 25,000 people across 24 locations in eight states. The new facility in Hillsboro will support the production of "advanced delivery devices for medicines," including pre-filled syringes and auto-injectors.
Written by urgent.news from NZZ Wirtschaft's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
